NCT04024501 - A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2019

Primary Completion Date

September 18, 2019

Study Completion Date

September 18, 2019

Conditions

Chronic Kidney Disease

Interventions

DRUG

Verinurad ER8 capsule formulation (fasted)

Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.

DRUG

Verinurad A-capsule formulation (fasted)

Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.

DRUG

Verinurad A-capsule formulation (fed)

Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).

DRUG

Verinurad B-capsule formulation (fasted)

Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.

DRUG

Verinurad B-capsule formulation (fed)

Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).

Trial Locations (1)

14050

Research Site, Berlin